Vmp-like sequences of pathogenic Borrelia
US-9212218-B2 · Dec 15, 2015 · US
Anti-pseudomonas Psl binding molecules and uses thereof
US10370436B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10370436-B2 |
| Application number | US-201615192072-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 24, 2016 |
| Priority date | Jun 10, 2011 |
| Publication date | Aug 6, 2019 |
| Grant date | Aug 6, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of blocking attachment of Pseudomonas aeruginosa to epithelial cells comprising contacting a mixture of epithelial cells and P. aeruginosa with an antibody or antigen-binding fragment thereof, wherein the antibody or antibody-binding fragment thereof comprises a set of complementarity determining regions (CDRs) VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3, wherein: VHCDR1 comprises SEQ ID NO: 47, VHCDR2 comprises SEQ ID NO: 48, VHCDR3 comprises SEQ ID NO: 75, VLCDR1 comprises SEQ ID NO: 50, VLCDR2 comprises SEQ ID NO: 51, and VLCDR3 comprises SEQ ID NO: 52. 2. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is humanized, chimeric, or fully human. 3. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is a Fab fragment, a Fab′ fragment, a F(ab)2 fragment or a single chain Fv (scFv). 4. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is monoclonal. 5. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) comprising SEQ ID NO: 74 and a light chain variable region (VL) comprising SEQ ID NO: 12.
Assignees
Inventors
Classifications
Drugs for disorders of the blood or the extracellular fluid · CPC title
Antibacterial agents · CPC title
Drugs for disorders of the senses · CPC title
for bone diseases, e.g. rachitism, Paget's disease · CPC title
for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10370436B2 cover?
- The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
- Who is the assignee on this patent?
- Medimmune Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K39/40. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).